1548 / 1708
P
< .001
0.25
0.50
0.75
1.00
0
1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
OS (probability)
EPN_PFA
EPN_PFB
54 51 42 38 33 29 28 24 21 16 10
EPN_PFA
130 120 111 99 84 76 64 52 43 32 24
EPN_PFB
No. at risk
P
= .00141
0.25
0.50
0.75
1.00
0
1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
PFS (probability)
EPN_PFA
EPN_PFB
54 48 36 30 25 23 23 20 17 13 7
EPN_PFA
130 116 104 91 77 69 58 46 38 28 22
EPN_PFB
No. at risk
A
B
Fig A4.
Survival by subgroup in patients with an age at diagnosis of greater than 10 years for (A) progression-free survival (PFS) and (B) overall survival (OS).
A
P
< .001
0.25
0.50
0.75
1.00
0
1 2 3 4 5 6 7 8 9 10
PFS (years)
PFS (probability)
176 149 124 105 92 86 68 58 47 37 29
248 204 150 118 97 84 76 63 46 38 33
95 66 51 40 31 28 23 17 13 10 6
140 100 72 50 36 28 18 15 14 11 10
Female/GTR
Male/GTR
Female/STR
Male/STR
No. at risk
Female/GTR
Male/GTR
Female/STR
Male/STR
B
P
< .001
0.25
0.50
0.75
1.00
0
1 2 3 4 5 6 7 8 9 10
Follow-Up Time (years)
OS (probability)
Female/GTR
Male/GTR
Female/STR
Male/STR
176 162 144 130 113 105 83 73 61 48 37
248 225 194 159 133 116 103 87 64 53 43
95 80 71 58 49 40 30 23 16 11 8
140 118 100 77 63 44 35 24 22 19 14
Female/GTR
Male/GTR
Female/STR
Male/STR
No. at risk
Fig A5.
Sex as a function of extent of resection in EPN_PFA for (A) progression-free survival (PFS) and (B) overall survival (OS).
P
values were determined using the
log-rank test. GTR, gross total resection; STR, subtotal resection.
www.jco.org© 2016 by American Society of Clinical Oncology
Treatment of Posterior Fossa Ependymoma Subgroups
from 139.18.224.1
Information downloaded from
jco.ascopubs.organd provided by at UNIVERSITAETSKLINIKUM LEIPZIG on June 20, 2016
Copyright © 2016 American S ciety of Clinical Oncology. All rights reserved.